127 related articles for article (PubMed ID: 38316186)
1. Minimal impact of low-density lipoprotein apheresis on vancomycin serum concentration: A case report.
Hiyama Y; Tomita T; Matsuo H
J Infect Chemother; 2024 Aug; 30(8):812-814. PubMed ID: 38316186
[TBL] [Abstract][Full Text] [Related]
2. Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Matsuda T; Suzuki Y; Ueda Y; Koide H
ASAIO J; 2003; 49(4):430-4. PubMed ID: 12918586
[TBL] [Abstract][Full Text] [Related]
3. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans.
Nakamura T; Ushiyama C; Osada S; Inoue T; Shimada N; Koide H
J Diabetes Complications; 2003; 17(6):349-54. PubMed ID: 14583180
[TBL] [Abstract][Full Text] [Related]
4. Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with peripheral arterial disease.
Kamimura M; Matsuo M; Miyahara T; Kimura K; Matsumoto K; Nakaya T; Abe T; Akizawa T
Ther Apher; 2002 Dec; 6(6):467-70. PubMed ID: 12460413
[TBL] [Abstract][Full Text] [Related]
5. LDL apheresis reduces the susceptibility of LDL to in vitro oxidation in a diabetic patient with hemodialysis treatment.
Inoue I; Takahashi K; Kikuchi C; Katayama S
Diabetes Care; 1996 Oct; 19(10):1103-7. PubMed ID: 8886556
[TBL] [Abstract][Full Text] [Related]
6. LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis.
Sato E; Amaha M; Nomura M; Matsumura D; Ueda Y; Nakamura T
Diabetes Res Clin Pract; 2014 Nov; 106(2):241-6. PubMed ID: 25306260
[TBL] [Abstract][Full Text] [Related]
7. Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia.
Wada T; Hara A; Muso E; Maruyama S; Kato S; Furuichi K; Yoshimura K; Toyama T; Sakai N; Suzuki H; Tsukamoto T; Miyazaki M; Sato E; Abe M; Shibagaki Y; Narita I; Goto S; Sakamaki Y; Yokoyama H; Mori N; Tanaka S; Yuzawa Y; Hasegawa M; Matsubara T; Wada J; Tanabe K; Masutani K; Abe Y; Tsuruya K; Fujimoto S; Iwatsubo S; Tsuda A; Suzuki H; Kasuno K; Terada Y; Nakata T; Iino N; Sofue T; Miyata H; Nakano T; Ohtake T; Kobayashi S;
Clin Exp Nephrol; 2021 Jan; 25(1):1-8. PubMed ID: 32857255
[TBL] [Abstract][Full Text] [Related]
8. Effects of LDL apheresis and vitamin E-modified membrane on carotid atherosclerosis in hemodialyzed patients with arteriosclerosis obliterans.
Nakamura T; Kawagoe Y; Matsuda T; Takahashi Y; Sekizuka K; Ebihara I; Koide H
Kidney Blood Press Res; 2003; 26(3):185-91. PubMed ID: 12886046
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
[TBL] [Abstract][Full Text] [Related]
10. Effect of low-density lipoprotein apheresis on urinary protein and podocyte excretion in patients with nephrotic syndrome due to diabetic nephropathy.
Nakamura T; Kawagoe Y; Ogawa H; Ueda Y; Hara M; Shimada N; Ebihara I; Koide H
Am J Kidney Dis; 2005 Jan; 45(1):48-53. PubMed ID: 15696443
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
Morimoto S; Yano Y; Maki K; Sawada K; Iwasaka T
Am J Nephrol; 2007; 27(6):643-8. PubMed ID: 17878713
[TBL] [Abstract][Full Text] [Related]
12. Effect of Low-Density Lipoprotein Apheresis on Quality of Life in Patients with Diabetes, Proteinuria, and Hypercholesterolemia.
Hara A; Wada T; Muso E; Maruyama S; Kato S; Furuichi K; Yoshimura K; Toyama T; Sakai N; Suzuki H; Tsukamoto T; Miyazaki M; Sato E; Abe M; Shibagaki Y; Narita I; Goto S; Sakamaki Y; Yokoyama H; Mori N; Tanaka S; Yuzawa Y; Hasegawa M; Matsubara T; Wada J; Tanabe K; Masutani K; Abe Y; Tsuruya K; Fujimoto S; Iwatsubo S; Tsuda A; Suzuki H; Kasuno K; Terada Y; Nakata T; Iino N; Sofue T; Miyata H; Nakano T; Ohtake T; Kobayashi S;
Blood Purif; 2023; 52(4):373-381. PubMed ID: 36521435
[TBL] [Abstract][Full Text] [Related]
13. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy.
Barth RH; DeVincenzo N
Kidney Int; 1996 Sep; 50(3):929-36. PubMed ID: 8872968
[TBL] [Abstract][Full Text] [Related]
14. Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
Kawano M; Kuroda Y; Terao M; Yaginuma T; Kawakami M; Kanazawa Y
Clin Chim Acta; 2002 Apr; 318(1-2):91-5. PubMed ID: 11880117
[TBL] [Abstract][Full Text] [Related]
15. Effect of beta-blocker therapy on serum lipoprotein profiles in patients on renal dialysis and in diabetic nephropathy.
Kontessis PS; Jayathissa SA; Walker JD; Mattock MB; Williams DG; Viberti GC
Diabetes Res; 1993; 23(3):93-104. PubMed ID: 7712687
[TBL] [Abstract][Full Text] [Related]
16. Low-density lipoprotein apheresis retards the progression of hyperlipidemic overt diabetic nephropathy.
Nakao T; Yoshino M; Matsumoto H; Okada T; Han M; Hidaka H; Shino T; Yamada C; Nagaoka Y; Miyahara T
Kidney Int Suppl; 1999 Jul; 71():S206-9. PubMed ID: 10412777
[TBL] [Abstract][Full Text] [Related]
17. LDL-Apheresis for diabetic nephropathy: a possible new tool.
Kobayashi S
Nephron; 1998 Aug; 79(4):505-6. PubMed ID: 9689183
[No Abstract] [Full Text] [Related]
18. Vancomycin during the Last Hour of the Hemodialysis Session: A Pharmacokinetic Analysis.
Ghouti-Terki L; Chasseuil E; Rabot N; Paintaud G; François M; Birmelé B; Darrouzain F; Büchler M; Halimi JM; Ternant D
Nephron; 2017; 135(4):261-267. PubMed ID: 28152540
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Vancomycin in Critically Ill Patients Undergoing Sustained Low-Efficiency Dialysis.
Rider TR; Silinskie KM; Hite MS; Bress J
Pharmacotherapy; 2020 Oct; 40(10):1036-1041. PubMed ID: 32866291
[TBL] [Abstract][Full Text] [Related]
20. A Bayesian Model to Describe Factors Influencing Trough Levels of Vancomycin in Hemodialysis Patients.
Sansot C; Kalbacher E; Lemoine S; Bourguignon L; Fauvel JP; Ducher M
Nephron; 2015; 131(2):131-7. PubMed ID: 26376164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
